🇺🇸 FDA
Pipeline program

Orelabrutinib

I2021001524

Phase 2 small_molecule active

Quick answer

Orelabrutinib for Primary Central Nervous System Hodgkin Lymphoma is a Phase 2 program (small_molecule) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).

Program details

Company
The First People's Hospital of Lianyungang
Indication
Primary Central Nervous System Hodgkin Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials